Spots Global Cancer Trial Database for fgfr3
Every month we try and update this database with for fgfr3 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma | NCT02401542 | Locally Advance... Urinary Bladder... Urological Dise... | Vofatamab Docetaxel Placebo | 18 Years - | Rainier Therapeutics | |
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | NCT04197986 | Upper Tract Uro... Urothelial Blad... | Infigratinib Placebo | 18 Years - | QED Therapeutics, Inc. | |
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | NCT04917809 | Bladder Cancer Recurrent Bladd... FGFR3 Gene Muta... | Erdafitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | NCT05363605 | Advanced Solid ... Head and Neck S... Bladder Carcino... Susceptible FGF... FGFR3 FGFR3 Overexpre... FGFR3 Receptor FGFR3 Protein O... Ovarian Cancer Colorectal Canc... Breast Cancer Liver Cancer Lung Cancer Gastric Cancer | [225Ac]-FPI-196... [111In]-FPI-196... vofatamab | 18 Years - | Fusion Pharmaceuticals Inc. | |
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | NCT04197986 | Upper Tract Uro... Urothelial Blad... | Infigratinib Placebo | 18 Years - | QED Therapeutics, Inc. | |
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | NCT01752920 | Solid Tumor | Derazantinib lo... Derazantinib mi... Derazantinib hi... Derazantinib at... | 18 Years - | Basilea Pharmaceutica |